EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Steminent Biotherapeutics Inc. (7729) fair value: what the stock is really worth

We calculate from audited financials what Steminent Biotherapeutics Inc. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0007729006

SB Thin data Sep 13, 2026

Steminent Biotherapeutics Inc.

7729 · TWO

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value 140.33 TWD · Undervalued (+23%)
!Quality 23/100
!Weak Growth (revenue 3y −73.7 %/yr)
!negative free cash flow
!Mixed vs. peers (4/7)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Steminent Biotherapeutics Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

120.50 TWD 40.90 TWD Fair Value 140.33 TWD Dec 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 13, 2026.

How to read this chart

9‑month range 40.90 TWD – 120.50 TWD · fair‑value band 92.48 TWD – 175.28 TWD · the 114.50 TWD price screens below the 140.33 TWD fair value. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States.

Show more

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.

Stock analysis

Steminent Biotherapeutics Inc. (7729) currently trades at 114.50 TWD, while our model-based Fair Value estimate is 140.33 TWD, implying the stock looks roughly 18.4% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 92.48 TWD (bear) to 175.28 TWD (bull), the price of 114.50 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Steminent Biotherapeutics Inc. reported revenue of 0 TWD in FY2024 versus 51.5M TWD in FY2020. Reported net income was −174M TWD in FY2025.

Key figures

Market cap 8.3B TWD (≈ $263M) · EPS (TTM) −2.91 TWD · Return on equity −36.4% · Return on assets (EBIT) −30.6% · Free cash flow −140M TWD · Net cash 142M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades near its 52-week high and 188% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 23%, 7729 screens cheaper than that median.

Fair Value models

Bear 92.48 TWD Fair Value 140.33 TWD Bull 175.28 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 3.73 TWD 5.00 TWD 7.46 TWD 51
All 1 models by family
Asset-Based
NCAV (Graham) 3.73 TWD 5.00 TWD 7.46 TWD 51

Open the full fair value analysis →

Notify me when 7729 reaches fair value

Put 7729 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 23/100

Of which business quality 31 · Market factors (momentum, volatility) 80

Profitability 0
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 17
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 88
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+48.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−73.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−83.5% (2020) → −13,970.1% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 7729, get fair value alerts →

Compare Steminent Biotherapeutics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 645 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Profitability
Return on assets −19% · Below median
Net margin (TTM) 0% · Below median
Operating margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.32× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)63 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $515.44 $566.98 +10%
Regeneron Pharmaceuticals, Inc REGN $781.49 $1,241 +59%
argenx SE ARGX €853.80 €752.12 −12%
BeOne Medicines AG 688235 ¥247.30 ¥124.62 −50%
Samsung Biologics Co 207940 1,415,000 KRW 1,556,500 KRW +10%
Alnylam Pharmaceuticals, Inc ALNY $248.68 $211.88 −15%
Royalty Pharma plc RPRX $58.61 $24.22 −59%
Celltrion, Inc 068270 178,200 KRW 74,519 KRW −58%
BioNTech SE BNTX $96.73 $63.31 −35%
Incyte Corporation INCY $121.47 $204.93 +69%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Steminent Biotherapeutics Inc. · Fair Value
140.33 TWD +18%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Steminent Biotherapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/7729

Frequently asked questions

Is Steminent Biotherapeutics Inc. (7729) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 140.33 TWD versus a price of 114.50 TWD, about +23% upside (undervalued).
What is the fair value of 7729?
Our model-based fair value for Steminent Biotherapeutics Inc. is 140.33 TWD (as of Sep 13, 2026), built from audited fundamentals. The current price: 114.50 TWD.
What is the quality score of 7729?
Steminent Biotherapeutics Inc. has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Steminent Biotherapeutics Inc. (7729)?
Our model-based price target is the fair value of 140.33 TWD (as of Sep 13, 2026) from 1 valuation models. Cautious scenario 92.48 TWD, optimistic scenario 175.28 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Steminent Biotherapeutics Inc. stock forecast for 2026?
Our models put fair value at 140.33 TWD, about +23% upside versus a price of 114.50 TWD (undervalued). Cautious scenario 92.48 TWD, optimistic scenario 175.28 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Steminent Biotherapeutics Inc. (7729)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Steminent Biotherapeutics Inc. it is 140.33 TWD per share (as of Sep 13, 2026), against a price of 114.50 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Steminent Biotherapeutics Inc. stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 7729 trades below its calculated fair value: price 114.50 TWD, fair value 140.33 TWD, a gap of about +23% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7729?
No. The price is what the market pays today (114.50 TWD); the fair value is what the company's own numbers justify (140.33 TWD). For Steminent Biotherapeutics Inc. the two are 25.83 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Steminent Biotherapeutics Inc. worth?
The market values Steminent Biotherapeutics Inc. at about 8.3B TWD (market capitalisation, as of Sep 13, 2026). Per share that is 114.50 TWD; our models calculate a fair value of 140.33 TWD per share.
What do the bullish and bearish scenarios say about 7729?
Our models span a range for Steminent Biotherapeutics Inc.: cautious scenario 92.48 TWD, base 140.33 TWD, optimistic 175.28 TWD per share (as of Sep 13, 2026, price 114.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Steminent Biotherapeutics Inc. (7729)?
Balance-sheet figures for Steminent Biotherapeutics Inc. (as of Sep 13, 2026): return on equity −36.4%. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is 7729 from its 52-week high?
Steminent Biotherapeutics Inc. trades at 114.50 TWD, about 20% below its 52-week high of 95.60 TWD and 188% above the low of 39.70 TWD (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 140.33 TWD is for.
Which stocks are comparable to Steminent Biotherapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Steminent Biotherapeutics Inc. stock attractive at the current price?
The data as of Sep 13, 2026: price 114.50 TWD, calculated fair value 140.33 TWD (+23%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7729 calculated?
We run Steminent Biotherapeutics Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 140.33 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Steminent Biotherapeutics Inc. currently trades 23 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Steminent Biotherapeutics Inc. right now?
A fairly wide model range (92.48 TWD to 175.28 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Steminent Biotherapeutics Inc.

How large is the market capitalisation of Steminent Biotherapeutics Inc. (7729)?
The market capitalisation of Steminent Biotherapeutics Inc. is 8.3B TWD (≈ $263M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Steminent Biotherapeutics Inc. (7729)?
Earnings per share at Steminent Biotherapeutics Inc. are −2.91 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Steminent Biotherapeutics Inc. (7729)?
The return on equity (ROE) of Steminent Biotherapeutics Inc. is −36.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Steminent Biotherapeutics Inc. (7729)?
On an EBIT basis the return on assets of Steminent Biotherapeutics Inc. is −30.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Steminent Biotherapeutics Inc. (7729) generate?
The free cash flow of Steminent Biotherapeutics Inc. is −140M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Steminent Biotherapeutics Inc. (7729) hold?
Steminent Biotherapeutics Inc. holds more cash than debt, 142M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Steminent Biotherapeutics Inc. in the live analysis

One click puts Steminent Biotherapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.